Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models"

Science

Volumn 340, Issue 6135, 2013, Pages

  Price, Ashleigh R ^a   Xu, Guilian ^a   Siemienski, Zoe B ^a   Smithson, Lisa A ^a   Borchelt, David R ^a   Golde, Todd E ^a   Felsenstein, Kevin M ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; BEXAROTENE; TETRALIN DERIVATIVE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; DRUG ABSORPTION; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG SYNTHESIS; DRUG TARGETING; LIVER WEIGHT; MOUSE; NONHUMAN; NOTE; PRIORITY JOURNAL; ANIMAL; BRAIN; MALE; METABOLISM;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; APOLIPOPROTEINS E; BRAIN; MALE; TETRAHYDRONAPHTHALENES;

MLCS; MLOWN;

EID: 84877986239     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.1234089     Document Type: Note

References (15)

1. P. E. Cramer et al., Science 335, 1503 (2012).
2. C. Querfeld, L. V. Nagelli, S. T. Rosen, T. M. Kuzel, J. Guitart, Expert Opin. Pharmacother. 7, 907 (2006).
3. A. Savonenko et al., Neurobiol. Dis. 18, 602 (2005).
4. T. E. Golde, L. Petrucelli, J. Lewis, Exp. Neurol. 223, 252 (2010).
5. S. Mandrekar-Colucci, G. E. Landreth, Expert Opin. Ther. Targets 15, 1085 (2011).
6. R. Koldamova, I. Lefterov, Curr. Alzheimer Res. 4, 171 (2007).
7. B. Bittner et al., Arzneimittelforschung 52, 684 (2002).
8. V. A. Miller et al., J. Clin. Oncol. 15, 790 (1997).
9. T. Kawarabayashi et al ., J. Neurosci. 21, 372 (2001).
10. G. Xu, C. C. Green, S. E. Fromholt, D. R. Borchelt, Alz. Res. Ther. 4, 12 (2012).
11. A. Wang, P. Das, R. C. Switzer 3rd, T. E. Golde, J. L. Jankowsky, J. Neurosci. 31, 4124 (2011).
12. Y. Levites et al., J. Clin. Invest. 116, 193 (2006).
13. D. M. Wilcock et al., J. Neurosci. 26, 5340 (2006).
14. B. J. Bacskai et al ., J. Neurosci. 22, 7873 (2002).
15. P. Chakrabarty et al., FASEB J. 24, 548 (2010).